
Shares of Biogen skyrocketed roughly 40 percent Tuesday after the biotech company said it will seek approval for an Alzheimer's treatment after abandoning the drug earlier this year.
Freddie Joyner has the story.
Shares of Biogen skyrocketed roughly 40 percent Tuesday after the biotech company said it will seek approval for an Alzheimer's treatment after abandoning the drug earlier this year.
Freddie Joyner has the story.